Prostate Cancer

Latest News

TALAPRO-2: Talazoparib/enzalutamide confers significant OS benefit in mCRPC
TALAPRO-2: Talazoparib/enzalutamide confers significant OS benefit in mCRPC

February 13th 2025

The investigators reported an HR for OS of 0.796 (95% CI, 0.661-0.958; 2-sided P = .0155) for talazoparib/enzalutamide vs enzalutamide/placebo.

FDA grants 510(k) clearance to AI-powered prostate cancer diagnostic
FDA grants 510(k) clearance to AI-powered prostate cancer diagnostic

February 10th 2025

Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Biomarkers in advanced prostate cancer: Liquid biopsy, ctDNA, and more

February 10th 2025

US FDA logo in white over a blue background. | Credit: US Food and Drug Administration
FDA Updates in Urology: January 2025

February 4th 2025

Phase 2 trial launches of opaganib plus darolutamide in mCRPC
Phase 2 trial launches of opaganib plus darolutamide in mCRPC

February 4th 2025

Video Series
Video Interviews
Podcasts
medical depiction of prostate cancer
Urology Times Speaking of Urology® logo

More News

© 2025 MJH Life Sciences

All rights reserved.